QIAGEN Announces Creation of Scientific Advisory Board and Agenda for Annual General Meeting in June 2021

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the creation of a Scientific Advisory Board as well as updates on the Supervisory Board ahead of the Annual General Meeting in June 2021.

Creation of new Scientific Advisory Board

The Managing Board and Supervisory Boards of QIAGEN have decided to create a new Scientific Advisory Board comprised of leading international experts. The new Board has a mandate to provide early evaluation of market and technology developments that could have an influence on QIAGEN’s development and positioning in the Life Sciences and Molecular Diagnostics.

The inaugural members of the Scientific Advisory Board include Dr. Peter Kaspar, who held multiple leadership positions at Roche Diagnostics and bioMérieux during his career in diagnostics, Life Sciences and pharmaceuticals; Prof. Patrice Nordmann, who serves as Chair of the Medical and Molecular Microbiology Department and other roles at the University of Fribourg, Switzerland; and Dr. Neville Sanjana, a Core Faculty Member at the New York Genome Center and an Assistant Professor at New York University. Additional members are expected to be appointed to the SAB in the coming months.

The Scientific Advisory Board will be chaired by Prof. Dr. Ross L. Levine, a member of the QIAGEN Supervisory Board as well as a U.S. physician-scientist focused on treating blood and bone marrow cancers. Dr. Metin Colpan, who is also a member of the Supervisory Board and a co-founder of QIAGEN, will serve as the vice chair.

Key areas of focus will involve QIAGEN’s five pillars of growth: Sample technologies that are used to isolate and purify nucleic acids; the QIAcuity series of digital PCR instruments; the QuantiFERON technology for latent disease testing, in particular latent tuberculosis; and the NeuMoDx and QIAstat-Dx solutions used for clinical molecular diagnostic testing.

Virtual AGM planned for June 29, 2021, Supervisory Committee renamed to include ESG focus

QIAGEN also announced today the agenda for the Annual General Meeting, which is to be held virtually on June 29, 2021. The meeting will be held virtually due to the COVID-19 pandemic and in line with Dutch legislation. The agenda includes regular recurring agenda items, including the discharge of the Managing Board and Supervisory Board, an advisory vote on the remuneration report, and proposals related to the Managing Board and Supervisory Board remuneration policies.